Bio-Rad Laboratories (BIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2015 | 12-2014 | 12-2013 | 12-2012 | 12-2011 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 457,549 | 413,251 | 331,551 | 463,388 | 574,231 |
| Marketable Securities | 332,928 | 284,384 | 277,369 | 457,685 | 238,884 |
| Receivables | 391,485 | 377,640 | 422,660 | 398,739 | 398,674 |
| Inventories | 490,224 | 470,997 | 516,245 | 455,120 | 433,510 |
| Income taxes - deferred | N/A | N/A | N/A | N/A | 53,777 |
| Other current assets | 11,041 | 61,747 | 79,017 | 69,260 | 0 |
| TOTAL | $1,777,596 | $1,716,367 | $1,757,479 | $1,936,682 | $1,798,155 |
| Non-Current Assets | |||||
| PPE Net | 437,690 | 428,836 | 414,401 | 416,938 | 349,501 |
| Investments And Advances | 719,840 | 389,309 | 377,870 | 293,613 | 0 |
| Intangibles | 709,974 | 754,669 | 783,958 | 756,357 | 728,430 |
| Other Non-Current Assets | 64,618 | 52,097 | 55,082 | 39,913 | 220,717 |
| TOTAL | $1,932,122 | $1,624,911 | $1,631,311 | $1,506,821 | $1,298,648 |
| Total Assets | $3,709,718 | $3,341,278 | $3,388,790 | $3,443,503 | $3,096,803 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | N/A | 265 | N/A | N/A | N/A |
| Accounts payable and accrued liabilities | 122,391 | 128,608 | 148,510 | 130,867 | 129,124 |
| Accrued Expenses | 157,857 | 153,426 | 130,658 | 135,955 | 112,564 |
| Other current liabilities | 101,783 | 102,581 | 116,573 | 113,043 | 114,787 |
| TOTAL | $441,351 | $446,761 | $487,472 | $472,400 | $459,115 |
| Non-Current Liabilities | |||||
| Long Term Debt | 433,883 | 435,710 | 435,615 | 732,414 | 731,698 |
| Deferred Revenues | 29,683 | 26,716 | 26,390 | 26,288 | 24,322 |
| Other Non-Current Liabilities | 110,506 | 118,735 | 116,850 | 108,026 | 76,286 |
| TOTAL | $777,864 | $709,362 | $714,596 | $955,563 | $893,306 |
| Total Liabilities | $1,219,215 | $1,156,123 | $1,202,068 | $1,427,963 | $1,352,421 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 29,362 | 29,102 | 28,794 | 28,499 | 28,200 |
| Common Shares | 3 | 3 | 3 | 3 | 3 |
| Retained earnings | 1,808,055 | 1,694,962 | 1,606,117 | 1,528,327 | 1,359,910 |
| Other shareholders' equity | 382,037 | 218,844 | 340,616 | 274,966 | 199,135 |
| TOTAL | $2,490,503 | $2,185,155 | $2,186,722 | $2,015,540 | $1,744,382 |
| Total Liabilities And Equity | $3,709,718 | $3,341,278 | $3,388,790 | $3,443,503 | $3,096,803 |